EU could pay over $10 billion for Pfizer and CureVac vaccines - source
BRUSSELS (Reuters) - The European Union could pay more than $10 billion to secure hundreds of millions of doses of the vaccine candidates being developed by Pfizer-BioNTech and CureVac, an EU official involved in the talks told Reuters.
The bloc has agreed to pay 15.50 euros ($18.34) per dose for the COVID-19 vaccine candidate being developed by Pfizer and BioNTech, according to the official.